17:21 , Jul 20, 2018 |  BC Week In Review  |  Company News

Roivant's China biotech reveals pipeline, pair of deals

Sinovant Sciences Ltd. (Shanghai, China) unveiled its pipeline, which contains four Phase III-ready assets, along with two new partnerships on July 17. Backed by Roivant Sciences GmbH (Basel, Switzerland) and Chinese private equity firm CITICPE, Sinovant...
15:41 , Jul 18, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Peptides A fibrin matrix loaded with synthetic laminin peptides that bind growth factors could be used for wound healing and tissue regeneration applications. The peptides are 24- and 19-mer synthetic analogs of human laminin α...
21:55 , Jul 17, 2018 |  BC Extra  |  Company News

Roivant's China biotech reveals pipeline, pair of deals

Sinovant Sciences Ltd. (Shanghai, China) unveiled its pipeline, which contains four Phase III-ready assets, along with two new partnerships on a newsy Tuesday. Backed by Roivant Sciences GmbH (Basel, Switzerland) and Chinese private equity firm CITICPE,...
18:57 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Novartis' infigratinib leads to 25.4% ORR in urothelial carcinoma patients

Data from 67 patients with previously treated advanced urothelial carcinoma with fibroblast growth factor (FGF) receptor 3 (FGFR3; CD333) alterations in an expansion cohort of an open-label, international Phase I trial showed that once-daily 125...
17:25 , Jun 29, 2018 |  BC Week In Review  |  Company News

China's Everest gets rights to Novartis' FGFR4 inhibitor

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) gained an exclusive, worldwide license to FGF401 from Novartis AG (NYSE:NVS; SIX:NOVN). The deal marks the second in-licensing of a fibroblast growth factor (FGF) receptor 4 (FGFR4; CD334) inhibitor...
14:25 , Jun 29, 2018 |  BC Week In Review  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas Venture,...
14:24 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Ultragenyx's Crysvita meets in Phase III for pediatric XLH

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) said Crysvita burosumab-twza (KRN23, UX023) met the primary endpoint of improving rickets compared with conventional therapy in the Phase III PIXLES trial to treat...
00:23 , Jun 26, 2018 |  BC Extra  |  Company News

China's Everest gets rights to Novartis' FGFR4 inhibitor

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) gained an exclusive, worldwide license to FGF401 from Novartis AG (NYSE:NVS; SIX:NOVN) on Monday. The deal marks the second in-licensing of a fibroblast growth factor (FGF) receptor 4 (FGFR4;...
11:27 , Jun 25, 2018 |  BC Extra  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas Venture,...
03:35 , Jun 16, 2018 |  BioCentury  |  Product Development

MATCH’s long game

Although three of the first four arms in NCI-MATCH missed their endpoints, the results suggest the basket trial is doing what it is supposed to -- finding efficacy signals in rare cancers. It’s also yielded...